摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-4-ethyl-4-hydroxy-6-iodo-7-(prop-2-yn-1-yl)-1,7-dihydro-3H-pyrano[3,4-c]pyridino-3,8(4H)-dione | 174092-80-9

中文名称
——
中文别名
——
英文名称
(S)-4-ethyl-4-hydroxy-6-iodo-7-(prop-2-yn-1-yl)-1,7-dihydro-3H-pyrano[3,4-c]pyridino-3,8(4H)-dione
英文别名
(S)-4-Ethyl-4-hydroxy-6-iodo-3-oxo-7-propargyl-1H-pyrano[3,4-c]-8-pyridone;(4S)-4-ethyl-4-hydroxy-6-iodo-7-prop-2-ynyl-1H-pyrano[3,4-c]pyridine-3,8-dione
(S)-4-ethyl-4-hydroxy-6-iodo-7-(prop-2-yn-1-yl)-1,7-dihydro-3H-pyrano[3,4-c]pyridino-3,8(4H)-dione化学式
CAS
174092-80-9
化学式
C13H12INO4
mdl
——
分子量
373.147
InChiKey
BMUJHRFJDYDWFP-ZDUSSCGKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    599.4±50.0 °C(Predicted)
  • 密度:
    1.85±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    66.8
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    A General Synthetic Approach to the (20S)-Camptothecin Family of Antitumor Agents by a Regiocontrolled Cascade Radical Cyclization of Aryl Isonitriles
    摘要:
    A general and efficient synthesis of (20S)-camptothecin (1a) is reported. A key common intermediate containing the pyridone and lactone (DE) rings of camptothecin and most derivatives was constructed from 2-trimethylsilyl-6-methoxypyridine by a series of metalation reactions and a Heck cyclization to provide an achiral bicyclic enol ether. Sharpless asymmetric dihydroxylation followed by lactol oxidation and iododesilylation produced the key intermediate in 94% enantiomeric excess. Alkylation with propargyl bromide and a cascade radical reaction with phenyl isonitrile then produced 1a. About 20 other penta- and hexacyclic analogues of camptothecin with differing single or multiple substituents at C7, C9, C10, C11, and/or C12 were made by changing the propargylating agent and the isonitrile. Included among these are several drug candidates and the approved drugs topotecan and irinotecan. The synthesis of the prodrug irinotecan is direct one that does not pass through the active metabolite. The use of ortho-trimethylsilyl-substituted isonitriles allows the regioselective synthesis of camptothecin analogues in cases where isomeric mixtures are formed from the parent isonitriles. The synthesis of the derivatives relies on the broad scope and functional group tolerance of the key cascade radical reaction.
    DOI:
    10.1002/(sici)1521-3765(199801)4:1<67::aid-chem67>3.0.co;2-f
  • 作为产物:
    描述:
    4-Ethyl-8-methoxy-6-trimethylsilanyl-1H-pyrano[3,4-c]pyridine四氧化锇 、 hydroquinindine-2,5-diphenyl-4,6-pyrimidinediyl diether 、 氢碘酸一氯化碘 、 sodium hydride 、 calcium carbonate 、 lithium bromide 作用下, 以 乙二醇二甲醚N,N-二甲基甲酰胺 为溶剂, 生成 (S)-4-ethyl-4-hydroxy-6-iodo-7-(prop-2-yn-1-yl)-1,7-dihydro-3H-pyrano[3,4-c]pyridino-3,8(4H)-dione
    参考文献:
    名称:
    Curran, Dennis P.; Ko, Sung-Bo; Josien, Hubert, Angewandte Chemie, 1995, vol. 107, # 23/24, p. 2948 - 2950
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Visible-Light-Induced Radical Cascade Cyclization: Synthesis of (20<i>S</i>)-Camptothecin, SN-38 and Irinotecan
    作者:Yao Yuan、Wuheng Dong、Xiaoshuang Gao、Xiaomin Xie、Dennis P. Curran、Zhaoguo Zhang
    DOI:10.1002/cjoc.201800358
    日期:2018.11
    irinotecan and SN‐38 were successfully synthesized by a photocatalyzed radical cascade cyclization from an N‐propargyl iodopyridinone and an arylisonitrile under visible light with a ruthenium catalyst. This synthetic method provided a useful entry into composing camptothecin family of antitumor agents in good yields under mild reaction conditions without the use of heavy metal reagents.
    (20 S)-喜树碱伊立替康和SN-38是在可见光下用催化剂通过N-炔丙基碘吡啶并酮和芳基异腈通过光催化的自由基级联环化反应成功合成的。这种合成方法在不使用重属试剂的情况下,在温和的反应条件下,以高收率组成了喜树碱抗肿瘤药家族,提供了有用的途径。
  • Intermediates in the synthesis of camptothecin and related compounds and synthesis thereof
    申请人:University of Pittsburgh
    公开号:US06252079B1
    公开(公告)日:2001-06-26
    The present invention provides a short, convergent total synthesis of irinotecan and derivative compounds which comprises of a novel 4+1 radical annulation wherein the precursor is reacted with an aryl isonitrile having the formula wherein X is Br or I, and R4 is an alkyl group, an allyl group, a propargyl group or a benzyl group, and R16 is H, a C1-C6 alkoxy group, a group wherein p is an integer between 4 and 12, or a C1-C12 acyclic dialkylamino group. The present invention also provides novel chemical intermediates for such 4+1 radical annulations.
    本发明提供了伊立替康及其衍生化合物的短、收敛的全合成方法,包括一种新颖的4+1自由基环合反应,其中前体物质与具有以下结构的芳基异腈发生反应:其中X为Br或I,R4为烷基、烯丙基、丙炔基或苄基,R16为H、C1-C6烷氧基、p为4至12之间的整数的羟基,或C1-C12非环二烷基基基团。本发明还提供了用于这种4+1自由基环合反应的新型化学中间体。
  • Novel intermediates in the synthesis of camptothecin and related compounds and synthesis thereof
    申请人:——
    公开号:US20010029298A1
    公开(公告)日:2001-10-11
    The present invention provides a short, convergent total synthesis of camptothecin and related compounds which consists of a novel 4+1 radical annulation. The present invention also provides novel chemical intermediates for such 4+1 radical annulations.
    本发明提供了一种喜树碱及相关化合物的简短、趋同的全合成方法,该方法包括一种新型的 4+1 自由基环化反应。本发明还提供了用于此类 4+1 自由基环化的新型化学中间体。
  • Selective N-functionalization of 6-substituted-2-pyridones
    作者:Hui Liu、Sung-Bo Ko、Hubert Josien、Dennis P. Curran
    DOI:10.1016/0040-4039(95)01917-7
    日期:1995.12
    6-Substituted-2-pyridones can be selectively N-alkylated by treatment with NaH/LiBr in a mixture of DMF and DME. Yields of N-propargylated, N-allylated, and other N-functionalized products are good, and only small amounts of the isomeric O-alkylated product (<10%) are typically formed.
  • US6211371B1
    申请人:——
    公开号:US6211371B1
    公开(公告)日:2001-04-03
查看更多

同类化合物

龙胆胺 龙胆定碱 西藏龙胆碱 萤光红BK 苯酰胺,N-(1,5,7,8-四氢-4-羰基-4H-吡喃并[4,3-b]吡啶-3-基)- 秦艽碱丙 秦艽甲素 盐酸伊立替康杂质20 溶剂红197 吡喃联氮基[2,1-c][1,4]苯并噁嗪,1,2,3,4,4a,5-六氢-(9CI) 伊立替康杂质29 α.-D-核-七吡喃糖苷-6-酮糖,甲基3,7-二脱氧-2-O-甲基-4-O-(苯基甲基)- N-(3,4-二氢-2H-吡喃并[3,2-b]吡啶-4-基)-n-甲基甘氨酸 N-(2-(4-甲氧苯基)乙烯基)-吡咯烷-2,5-二酮 8-碘-3,4-二氢-2H-吡喃并[3,2-c]吡啶 7H-噻喃并[2,3-d]嘧啶 7-溴-2H-吡喃并[3,2-b]吡啶 7-氯-3,4-二氢-2H-吡喃并[2,3-B]吡啶 7-乙基-10-羟基喜树碱中间体 7,8-二氢-6H-硫代吡喃并[3,2-d]嘧啶-2,4-二醇 7,8-二氢-5H-吡喃并[4,3-b]吡啶-3-胺 7,8-二氢-2-(甲硫基)-3H-噻喃并[3,2-d]嘧啶-4(6H)-酮 6H-噻喃并[3,2-d]嘧啶 6-碘-3,4-二氢-2h-吡喃并[3,2-b]吡啶-8-甲醛 6-碘-3,4-二氢-2h-吡喃并[3,2-b]吡啶 6-甲基-3,4-二氢吡喃并[4,3-d]吡啶-1-酮 6-溴-2H-吡喃并[2,3-b]吡啶-4(3H)-酮 6-溴-2-苯基-2H-吡喃并[2,3-b]吡啶 6-溴-2-(4-甲基苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-溴-2-(3,4-二氯苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-氯-2-(4-氯苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-氯-2-(3,4-二氯苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-(4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基)-3,4-二氢-2H-吡喃[2,3-b]吡啶 6,8-二碘-3,4-二氢-2H-吡喃[3,2-b]吡啶 5H-噻喃并[2,3-d]嘧啶 5-氧杂-10-氮杂三环[6.2.1.04,9]十一碳-1,3,7,9-四烯 5,8-二氢-6H-吡喃并[3,4-b]吡啶 4H-吡喃并[2,3-b]吡啶-4-酮,6-氯-2,3-二氢-2-甲基-,(R)- 4H-吡喃并[2,3-b]吡啶-4-酮 4-羟甲基-3,4-二氢-2H-吡喃[3,2-B]吡啶-4-醇 4-甲基-7-吗啉基-2H-吡喃并[2,3-b]吡啶-2-酮 4-乙基-7,8-二氢-4-羟基-1H-吡喃并[3,4-f]吲嗪-3,6,10(4H)-三酮 4,4',5'-三甲基氮杂补骨脂素 4'-乙基-7',8'-二氢-螺[1,3-二氧戊环-2,6'(3'H)-[1H]吡喃并[3,4-f]吲哚嗪]-3',10'(4′H)-二酮-d5 4'-乙基-7',8'-二氢-4'-羟基-螺[1,3-二氧戊环-2,6'(3'H)-[1H]吡喃并[3,4-f]吲哚嗪]-3′,10′(4′H)-二酮-d5 3-异噻唑甲酰胺,N-(4-氯-7,8-二氢-5H-吡喃并[4,3-b]吡啶-3-基)- 3-(二烯丙基氨基)-7-氧代-7H-苯并吡喃并[3',2':3,4]吡啶并[1,2-a]苯并咪唑-6-甲腈 3-(4-羟苯在)-4H-吡喃[2,3-B]吡啶-4-酮 3,4-二氢-4-亚甲基-(9ci)-2H-吡喃并[3,2-b]吡啶 3,4-二氢-2h-吡喃并[3,2-b]吡啶-8-羧酸